Skip to main content
. Author manuscript; available in PMC: 2015 May 21.
Published in final edited form as: Circulation. 2010 Feb 22;121(9):1069–1077. doi: 10.1161/CIRCULATIONAHA.109.906479

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Relative risk of allocation to statin compared with placebo in women in relation to CVD in exclusively primary prevention trials (panel A) and predominantly or exclusively primary prevention trials (panel B). Similarly for total mortality (panels C and D). The size of the squares is proportional to the number of events. Mean age, % diabetic, and statin dose were, respectively, as follows: AFCAPS/TexCAPS 63 years, 3%, lovastatin 20–40 mg/day; ALLHAT-LLA 66 years, 35%, pravastatin 20–40 mg/day; ASCOT-LLA 63 years, 24%, atorvastatin 10 mg/day; MEGA 60 years, 18%, pravastatin 10–20 mg/day; JUPITER 69 years, 0%, rosuvastatin 20 mg/day.